Replies to post #4 on Ventyx Biosciences Inc (VTYX)

[Invest-in-America]

THANKS!!

[DewDiligence]

VTYX—(-79%/AH)—terminates VTX958 psoriasis and PsA programs following phase-2 readout:

https://finance.yahoo.com/news/ventyx-biosciences-announces-results-phase-210100036.html

Although the trial achieved its primary endpoint, the magnitude of efficacy observed did not meet our internal target to support advancement of VTX958 in plaque psoriasis. Accordingly, we will terminate ongoing activities in the Phase 2 plaque psoriasis trial effective immediately. Based on these results, we have also elected to terminate the ongoing Phase 2 trial of VTX958 in psoriatic arthritis.

The ongoing Phase 2 trial of VTX958 in Crohn’s disease will continue to enroll and we intend to conduct an interim efficacy analysis in the first quarter of 2024.

VTX952 is a TYK2 inhibitor, the same drug class as BMY’s Sotyktu.